Arbutus Biopharma Corporation
ABUS
$3.15
$0.092.94%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 36.44% | 0.40% | -10.75% | 7.44% | 3.94% |
| Total Depreciation and Amortization | -0.89% | -5.62% | 0.28% | -1.11% | -2.71% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 84.70% | -47.47% | 100.92% | 522.99% | -86.95% |
| Change in Net Operating Assets | 90.84% | -190.61% | 196.47% | -292.27% | 143.97% |
| Cash from Operations | 50.26% | -42.97% | 24.83% | -11.58% | 20.62% |
| Capital Expenditure | -- | 100.00% | 98.95% | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 212.61% | -221.93% | -16.62% | -46.96% | 112.86% |
| Cash from Investing | 211.89% | -221.95% | -15.95% | -47.38% | 113.11% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -19.94% | -92.72% | -0.25% | 541.71% | 126.47% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -19.94% | -92.72% | -0.25% | 541.71% | 126.47% |
| Foreign Exchange rate Adjustments | -760.00% | 162.50% | 38.46% | -192.86% | 75.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 114.49% | -257.17% | 17.07% | 92.10% | 190.56% |